Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lifting symptom burden--how far off the ground are we?

Literature DB >> 18256858

Lifting symptom burden--how far off the ground are we?

Mellar P Davis, Jordanka Kirkova.

Abstract

Mesh：

Year: 2008 PMID： 18256858 DOI： 10.1007/s00520-007-0401-1

Source DB: PubMed Journal: Support Care Cancer ISSN： 0941-4355 Impact factor: 3.603

× No keyword cloud information.

48 in total

Review 1. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer.

Authors: Lesley J Fallowfield; Peter Harper
Journal: Lung Cancer Date: 2005-01-26 Impact factor: 5.705

2. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

Authors: Benjamin Movsas; Charles Scott; Corey Langer; Maria Werner-Wasik; Nicos Nicolaou; Ritsuko Komaki; Mitchell Machtay; Colum Smith; Rita Axelrod; Linda Sarna; Todd Wasserman; Roger Byhardt
Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544

3. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

Authors: Bradley J Monk; Helen Q Huang; David Cella; Harry J Long
Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544

Review 4. Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.

Authors: Kathleen Gondek; Pierre-Philippe Sagnier; Kim Gilchrist; J Michael Woolley
Journal: J Clin Oncol Date: 2007-11-10 Impact factor: 44.544

Review 5. Symptom burden: a concept analysis and implications for oncology nurses.

Authors: Roxanna L Gapstur
Journal: Oncol Nurs Forum Date: 2007-05 Impact factor: 2.172

6. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

Authors: Thomas E Witzig; Peter T Silberstein; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; James A Mailliard; Kendrith M Rowland; Steven R Alberts; James E Krook; Ralph Levitt; Roscoe F Morton
Journal: J Clin Oncol Date: 2004-09-27 Impact factor: 44.544

Review 7. Measuring health-related quality of life.

Authors: G H Guyatt; D H Feeny; D L Patrick
Journal: Ann Intern Med Date: 1993-04-15 Impact factor: 25.391

8. Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer: report on a survery by the European Society of Medical Oncology Taskforce on Palliative and Supportive Care.

Authors: Nathan I Cherny; Raphael Catane
Journal: Cancer Date: 2003-12-01 Impact factor: 6.860

9. Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy.

Authors: Max Dahele; Richard J E Skipworth; Lucy Wall; Anne Voss; Tom Preston; Kenneth C H Fearon
Journal: J Pain Symptom Manage Date: 2007-03-23 Impact factor: 3.612

10. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks.

Authors: Janice L Gabrilove; Edith A Perez; Dianne K Tomita; Greg Rossi; Charles S Cleeland
Journal: Cancer Date: 2007-10-01 Impact factor: 6.860

4 in total

1. Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.

Authors: Xiaobo Zhong; Emerson A Lim; Dawn L Hershman; Carol M Moinpour; Joseph Unger; Shing M Lee
Journal: J Oncol Pract Date: 2016-02-23 Impact factor: 3.840